Meiji Seika Pharma To Enhance India CMO Business Through Adcock Ingram Ltd. Of New Facility

Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo Japan, President and Representative Director: Daikichiro Kobayashi) announces that it has been decided to construct a new manufacturing facility at Adcock Ingram Ltd. (Headquarters: Bengaluru India, Managing Director: G.V. Ramireddy) in Bengaluru, India, to enhance its production capacity of the contract manufacturing organization (CMO) business.

Photo Insert: Rendering of the new manufacturing facility

Adcock Ingram Ltd., established in 2007, is a joint venture between Adcock Ingram Holdings Ltd., in South Africa, and Medreich Ltd. (Headquarters: Bengaluru India, Managing Director: Pankaj Garg), a wholly-owned subsidiary of Meiji Seika Pharma Co., Ltd. Adcock Ingram Ltd. manufactures pharmaceutical products, by contract manufacturing, and distributes for the South African, European and Oceanian markets.

By adding the new manufacturing facility, it can manufacture pharmaceutical products not only for the Adcock Ingram Group but also for other clients.

The new manufacturing facility is built at a subsidiary of Adcock Ingram Ltd. and is scheduled to start operation in March 2023. This report was originally released by Business Wire.

WEEKLY FEATURE : MVP Group Keeps Lights On During Pandemic